Want to see AMLX full AI Analyst Report?
Top Page
Amylyx Pharmaceuticals Inc
(NASDAQ:AMLX)
Select Model
Select Model
Rating:56Neutral
Price Target:
$22.50
▲(22.22% Upside)
Action:Reiterated
Date:08/06/26
The score is held back primarily by weak financial performance—minimal recent revenue, large ongoing losses, and persistent cash burn—despite low leverage. Support comes from constructive price trend/momentum (price above key moving averages with positive MACD) and a more optimistic near-term fundamental setup from the earnings call (imminent Phase III readout and launch preparations), while valuation remains constrained by a loss-making profile (negative P/E) and no dividend.
Positive Factors
Pivotal Phase III readout & NDA readiness
An imminent, conservatively powered pivotal readout and active NDA/launch preparation materially de-risk the path to commercialization. A positive outcome would create a durable revenue engine and shift the business from R&D to commercial execution, altering funding and margin dynamics.
Negative Factors
Absent revenue and persistent cash burn
With effectively no recurring revenue and sizable multi-year net losses, the company remains dependent on trial outcomes or financing to achieve self-sustaining cash flow. Persistent negative FCF implies structural funding needs until commercial revenues materialize.
Read all positive and negative factors
Positive Factors
Negative Factors
Pivotal Phase III readout & NDA readiness
An imminent, conservatively powered pivotal readout and active NDA/launch preparation materially de-risk the path to commercialization. A positive outcome would create a durable revenue engine and shift the business from R&D to commercial execution, altering funding and margin dynamics.
Read all positive factors
Amylyx Pharmaceuticals Inc (AMLX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.26B
Dividend YieldN/A
Average Volume (3M)1.63M
Price to Earnings (P/E)―
Beta (1Y)1.47
Revenue GrowthN/A
EPS Growth51.42%
CountryUS
Employees136
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.41
Shares Outstanding111,186,320
10 Day Avg. Volume1,486,119
30 Day Avg. Volume1,634,548
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)3.74
Price to Sales (P/S)0.00
P/FCF Ratio-9.25
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$28.43Price Target Upside54.42% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.47
Revenue Forecast (FY)N/A
Amylyx Pharmaceuticals Inc Business Overview & Revenue Model
Company Description
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipe...
How the Company Makes Money
null...
Amylyx Pharmaceuticals Inc Earnings Call Summary
Earnings Call Date:Aug 06, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 05, 2026
Earnings Call Sentiment Positive
The call conveyed clear momentum: a pivotal Phase III (LUCIDITY) nearing top-line readout, active NDA and launch preparations, formal disease recognition via ICD-10 coding, a defined prevalent patient population (~160,000 U.S. patients with ~75% RYGB), and continued pipeline progress (AMX0035, AMX0114, AMX0318). Financially, the company has a solid cash balance with runway into 2028 but experienced a quarter-over-quarter cash decline (~10.4%), rising operating/SG&A costs (SG&A +40.4% YoY), and an unspecified one-time legal charge. Key risks remain: the outcome of the blinded Phase III readout and potential label limitations, early-stage EAP activation constraints, and possible additional manufacturing obligations. Overall the positives (imminent pivotal readout, launch preparedness, market opportunity, and pipeline advancement) outweigh the operational and financial headwinds discussed.Positive Updates
Phase III LUCIDITY Nearing Top-Line Readout
Last participant completed last visit; database cleaning and lock pending; top-line data expected late August or early September 2026. Trial is powered conservatively (90% power to detect a 35% treatment effect even with up to a 50% placebo rate).
Negative Updates
Cash Balance Decline Quarter-to-Quarter
Cash and marketable securities decreased from $279.8M at the end of Q1 to $250.8M at the end of Q2 — a decline of $29.0M, or approximately a 10.4% decrease quarter-over-quarter.
Read all updates
Q2-2026 Updates
Positive
Negative
Phase III LUCIDITY Nearing Top-Line Readout
Last participant completed last visit; database cleaning and lock pending; top-line data expected late August or early September 2026. Trial is powered conservatively (90% power to detect a 35% treatment effect even with up to a 50% placebo rate).
Read all positive updates
Company Guidance
The company reiterated that LUCIDITY’s pivotal Phase III database is not yet locked but that last patient visits occurred in mid–late July with a top-line readout expected in late August or early September; the trial’s FDA‑agreed primary endpoint is reduction in the composite of Level 2 and Level 3 hypoglycemic events through week 16 and the study was conservatively powered (≥90% to detect a 35% treatment effect assuming up to a 50% placebo rate). Financially, Amylyx finished Q2 with $250.8 million in cash and marketable securities (down from $279.8M at Q1 end) and expects runway into 2028 to fund milestones including the LUCIDITY readout, potential FDA approval and a possible commercial launch in 2027; Q2 operating expenses were $45.7M (up 7% YoY) comprising R&D of $23.8M (vs $27.2M in Q2 2025), SG&A of $21.9M (vs $15.6M), and non‑cash stock‑based comp of $8.3M (vs $7.4M). Other program and operational metrics noted: prevalent U.S. PBH population ~160,000 (≈120,000 RYGB), CMO payment commitments of ~$35M through 2028, AMX0318 IND‑enabling work targeting a 2027 IND, an Early Access Program open to LUCIDITY completers and prior trial participants, an ICD‑10 code for PBH effective October 1, 2026, and that the company will enter a quiet period following database lock.Amylyx Pharmaceuticals Inc Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
62
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 87.37M | 380.79M | 22.23M | 0.00 |
| Gross Profit | -20.06M | -525.00K | 45.22M | 355.35M | 19.24M | 0.00 |
| EBITDA | -149.78M | -144.16M | -290.98M | 55.38M | -197.11M | -87.88M |
| Net Income | -152.09M | -144.74M | -301.74M | 49.27M | -198.38M | -87.93M |
Balance Sheet | ||||||
| Total Assets | 264.56M | 332.64M | 193.63M | 517.45M | 391.45M | 105.61M |
| Cash, Cash Equivalents and Short-Term Investments | 250.76M | 316.98M | 176.50M | 371.36M | 346.94M | 96.12M |
| Total Debt | 5.25M | 5.96M | 1.98M | 4.24M | 6.28M | 0.00 |
| Total Liabilities | 25.40M | 27.39M | 28.87M | 84.02M | 50.85M | 256.78M |
| Stockholders Equity | 239.17M | 305.26M | 164.76M | 433.43M | 340.61M | -151.17M |
Cash Flow | ||||||
| Free Cash Flow | -126.72M | -123.48M | -167.80M | 10.68M | -182.40M | -75.15M |
| Operating Cash Flow | -126.58M | -123.34M | -167.65M | 11.92M | -179.87M | -74.80M |
| Investing Cash Flow | -78.83M | 14.04M | 75.65M | 92.05M | -238.99M | -46.41M |
| Financing Cash Flow | 196.09M | 257.03M | 348.00K | 3.54M | 431.79M | 158.51M |
Amylyx Pharmaceuticals Inc Technical Analysis
Positive
18.41
Price Trends
17.26
Positive
16.24
Positive
15.01
Positive
Market Momentum
1.49
Negative
68.09
Neutral
85.85
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AMLX, the sentiment is Positive. The current price of 18.41 is below the 20-day moving average (MA) of 19.43, above the 50-day MA of 17.26, and above the 200-day MA of 15.01, indicating a bullish trend. The MACD of 1.49 indicates Negative momentum. The RSI at 68.09 is Neutral, neither overbought nor oversold. The STOCH value of 85.85 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AMLX.
Amylyx Pharmaceuticals Inc Risk Analysis
Amylyx Pharmaceuticals Inc disclosed 89 risk factors in its most recent earnings report. Amylyx Pharmaceuticals Inc reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Amylyx Pharmaceuticals Inc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | $2.04B | 13.98 | 20.06% | ― | 20.71% | -5.53% | |
58 Neutral | $5.84B | -972.00 | -3.51% | ― | -79.52% | -43.40% | |
57 Neutral | $2.28B | -5.19 | 101.55% | ― | 75.92% | -569.22% | |
56 Neutral | $2.26B | -13.72 | -55.69% | ― | ― | 51.42% | |
52 Neutral | $2.28B | -9.99 | -67.40% | ― | ― | -5.22% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $2.03B | -2.38 | -866.46% | ― | ― | 39.46% |
* Healthcare Sector Average
AMLX
Amylyx Pharmaceuticals Inc
22.82
15.18
198.69%
BCRX
BioCryst
9.38
1.08
13.01%
DNTH
Dianthus Therapeutics
108.92
90.16
480.60%
HRMY
Harmony Biosciences Holdings
38.41
4.22
12.34%
PHVS
Pharvaris
34.91
14.79
73.51%
BHVN
Biohaven Ltd.
14.66
-0.08
-0.54%
Amylyx Pharmaceuticals Inc Corporate Events
Executive/Board ChangesShareholder Meetings
Amylyx Shareholders Approve Directors, Auditor and Executive Pay
Positive
Jun 4, 2026
On June 4, 2026, Amylyx Pharmaceuticals, Inc. held its Annual Meeting of Stockholders, where investors elected George Mclean Milne Jr., Ph.D., and Paul Fonteyne as Class II directors for three-year terms ending at the 2029 annual meeting, reinforc...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.